Список литературы

Поставить закладку

Иммуносупрессия при трансплантации солидных органов / Под ред. С.В. Готье. – М. – Тверь: ООО «ИздательствоТриада», 2011; с.382.
Kidney transplantation: principles and practice. 6th ed. / Ed. by Sir Peter J. Morris and Stuart J. Knechtle // Philadelphia: Elsevier Saunders, 2008
Gore J.L., Pham P.T., Danovitch G.M. et al. Obesity and outcome following renal transplantation. Am J Transplant, 2006; 6: р.357–363.
Данович Габриэль М. Трансплантация почки / Пер. с англ. под ред. Я.Г. Мойсюка. – М: ГЭОТАР-Медиа, 2013; с.848.
Kable T., Alcaraz A., Budde K., Humke U., Karam G., Lucan M., Nicita G., Susal C. Трансплантация почки: Клинические рекомендации Европейской Ассоциации Урологов, 2010 / Перевод с англ под ред. Д.В. Перлина. – М.: АБВ-Пресс, 2010; с.100.
KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant, 2009; 9 Suppl : p.51-155.
Kasiske B.L., Maclean J.R., Snyder J.J. Acute myocardial infarction and kidney transplantation. J Am Soc Nephrol, 2006; 17: р.900–907.
Morrissey P.E., Flynn M.L., Lin S. Medication noncompliance and its implications in transplant recipients. Drugs, 2007; 67: р.1463–1481.
Kurtkoti J., Sakhuja V., Sud K. et al. The utility of 1- and 3-month protocol biopsies on renal allograft function: A randomized controlled study. Am J Transplan,t 2008; 8: 317 323.
Almeras C., Foulongne V., Garrigue V. et al. Does reduction in immunosuppression in viremic patients prevent BK virus nephropathy in de novo renal transplant recipients? A prospective study. Transplantation, 2008; 85: 1099–1104.
Мойсюк Я.Г., Столяревич Е.C., Томилина Н.А. Болезнь почечного трансплантата / Нефрология: национальное руководство // под ред. Н.А. Мухина. – М.: ГЭОТАР- Медиа, 2009; с.5 (Серия «Национальные руководства»).
Brennan D.C., Daller J.A., Lake K.D. et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl JMed, 2006; 355: р.1967–1977.
Webster A.C., Woodroffe R.C., Taylor R.S. et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomized trial data. BMJ, 2005; 331: 810
Ekberg H., Tedesco-Silva H., Demirbas A. et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med, 2007; 357: 2562–2575.
Rostaing L., Cantarovich D., Mourad G. et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation, 2005; 79: 807–814.
Solez K., Colvin R.B., Racusen L.C. et al. Banff ‘ 5 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘ ’). Am J Transplant, 2007; 7: 518–526.
Webster A.C., Pankhurst T., Rinaldi F. et al. Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: A systematic review of randomized trial data. Transplantation, 2006; 81: 953–965.
Nashan B. Review of the proliferation inhibitor everolimus. ExpertOpin Investig Drugs, 2002; 11: 1845–1857.
Knight S.R., Morris P.J. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation, 2008; 85: р.1675–1685.
Kyllonen L.E., Salmela K.T.. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: A prospective randomized single-center pilot study. Transplantation, 2006; 81: 1010–1015.